PRICE T ROWE ASSOCIATES INC /MD/ - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 78 filers reported holding LYELL IMMUNOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.2%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$9,830
-62.1%
6,686,197
-18.1%
0.00%
-75.0%
Q2 2023$25,953
+177.2%
8,161,094
+105.7%
0.00%
+300.0%
Q1 2023$9,364
-26.6%
3,967,338
+7.9%
0.00%
-50.0%
Q4 2022$12,755
-100.0%
3,675,686
-30.7%
0.00%
-66.7%
Q3 2022$38,898,000
+12.0%
5,306,607
-0.4%
0.01%
+50.0%
Q2 2022$34,735,000
+25.2%
5,327,496
-3.0%
0.00%
+33.3%
Q1 2022$27,744,000
-30.3%
5,493,922
+6.9%
0.00%
-25.0%
Q4 2021$39,794,000
-26.5%
5,141,291
+40.5%
0.00%
-20.0%
Q3 2021$54,157,000
+33.4%
3,659,270
+46.4%
0.01%
+25.0%
Q2 2021$40,600,0002,500,0000.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q4 2021
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$131,458,00059.13%
Apoletto Ltd 15,093,969$98,413,00027.22%
Foresite Capital Management IV, LLC 13,282,181$86,600,00023.32%
MIC Capital Management UK LLP 3,060,569$19,955,0003.90%
Alphabet Inc. 5,865,125$38,241,0002.08%
HSG Holding Ltd 3,045,997$19,860,0001.83%
Board of Trustees of The Leland Stanford Junior University 1,647,882$10,744,0000.72%
SG3 Management, LLC 600,000$3,912,0000.46%
KETTLE HILL CAPITAL MANAGEMENT, LLC 157,700$1,028,0000.26%
Artal Group S.A. 700,000$4,564,0000.24%
View complete list of LYELL IMMUNOPHARMA INC shareholders